SG11201408460UA - Inhibitors of the mir-15 family of micro-rnas - Google Patents
Inhibitors of the mir-15 family of micro-rnasInfo
- Publication number
- SG11201408460UA SG11201408460UA SG11201408460UA SG11201408460UA SG11201408460UA SG 11201408460U A SG11201408460U A SG 11201408460UA SG 11201408460U A SG11201408460U A SG 11201408460UA SG 11201408460U A SG11201408460U A SG 11201408460UA SG 11201408460U A SG11201408460U A SG 11201408460UA
- Authority
- SG
- Singapore
- Prior art keywords
- mir
- international
- lllll
- boulder
- family
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261662772P | 2012-06-21 | 2012-06-21 | |
US201361780352P | 2013-03-13 | 2013-03-13 | |
PCT/US2013/046960 WO2013192486A1 (fr) | 2012-06-21 | 2013-06-21 | Inhibiteurs de la famille mir-15 de micro-arn |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408460UA true SG11201408460UA (en) | 2015-01-29 |
Family
ID=49769409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408460UA SG11201408460UA (en) | 2012-06-21 | 2013-06-21 | Inhibitors of the mir-15 family of micro-rnas |
Country Status (17)
Country | Link |
---|---|
US (1) | US9163235B2 (fr) |
EP (1) | EP2863956A4 (fr) |
JP (1) | JP2015525081A (fr) |
KR (1) | KR20150036140A (fr) |
CN (1) | CN104540527A (fr) |
AR (1) | AR091539A1 (fr) |
AU (1) | AU2013277033A1 (fr) |
BR (1) | BR112014032239A2 (fr) |
CA (1) | CA2876105A1 (fr) |
EA (1) | EA201590070A1 (fr) |
HK (1) | HK1209621A1 (fr) |
IN (1) | IN2014DN10899A (fr) |
MD (1) | MD20150006A2 (fr) |
MX (1) | MX2014015641A (fr) |
SG (1) | SG11201408460UA (fr) |
TW (1) | TW201406774A (fr) |
WO (1) | WO2013192486A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX355408B (es) | 2012-06-21 | 2018-04-18 | Miragen Therapeutics Inc | Inhibidores a base de oligonucleotidos que comprenden un motivo de acido nucleico bloqueado. |
KR20150131365A (ko) | 2013-03-15 | 2015-11-24 | 미라젠 세러퓨틱스 인코포레이티드 | 브리지드 바이사이클릭 뉴클레오시드 |
US10443044B2 (en) | 2014-04-17 | 2019-10-15 | Ips Heart | Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds |
AU2015301221B2 (en) | 2014-08-04 | 2020-07-02 | MiRagen Therapeutics, Inc. | Inhibitors of MYH7B and uses thereof |
CN106559995A (zh) | 2014-08-07 | 2017-04-05 | 莱古路斯治疗法股份有限公司 | 靶向代谢紊乱的微小rna |
CN107636003A (zh) | 2015-01-20 | 2018-01-26 | 米拉根医疗股份有限公司 | miR‑92抑制剂及其用途 |
WO2017219170A1 (fr) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | Construction et application d'un vecteur lentiviral pour l'inhibition spécifique de l'expression de miarn-29a humain et de mir-424 humain |
CN110177544A (zh) | 2016-11-29 | 2019-08-27 | 普尔泰克健康有限公司 | 用于递送治疗剂的外泌体 |
CN106692175A (zh) * | 2016-12-26 | 2017-05-24 | 大连医科大学附属第二医院 | miR‑665‑3p抑制物在制备防治缺血再灌注损伤药物中的应用 |
US10941403B2 (en) | 2018-04-02 | 2021-03-09 | Oregon Health & Science University | Microrna inhibitors as anti-cancer therapeutics |
WO2021020412A1 (fr) | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Médicament à base d'acide nucléique ciblant le murf1 |
CN116438305A (zh) * | 2020-07-23 | 2023-07-14 | 法兰克福大学 | 用于治疗心力衰竭的miRNA的组合抑制 |
CN113599540B (zh) * | 2021-05-27 | 2023-05-23 | 山西医科大学 | miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2428569B1 (fr) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Molécules de micro arn |
PT1504126E (pt) | 2002-05-03 | 2014-06-02 | Univ Duke | Um método para regular a expressão génica |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
CN102304570B (zh) | 2002-11-13 | 2015-01-21 | 托马斯杰斐逊大学 | 用于癌症诊断和治疗的组合物和方法 |
EP2500440B1 (fr) | 2002-12-20 | 2015-12-16 | Celera Corporation | Polymorphismes génétiques associés à l'infarctus du myocarde, procédés de détection et utilisations associées |
EP1592791A2 (fr) | 2003-02-10 | 2005-11-09 | National Institute of Advanced Industrial Science and Technology | Regulation de l'expression genetique par interference d'adn |
US8145436B2 (en) | 2003-07-15 | 2012-03-27 | The Trustees Of The University Of Pennsylvania | Method and systems for identifying micro-RNA targets and synthesizing novel micro-RNAs and uses of the same |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
WO2005047505A2 (fr) | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Techniques et produits d'expression de micro arn |
WO2005017145A1 (fr) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | Methode d'identification reelle ou presumee d'un gene soumis a une regulation commandee par un arn fonctionnel et utilisation de cette methode |
WO2005028648A1 (fr) | 2003-09-22 | 2005-03-31 | Aichi Prefecture | Type de lymphome pathologique et procede d'evaluation de diagnostic |
US20080045417A1 (en) | 2003-10-14 | 2008-02-21 | Jan Weiler | Oligonucleotide Microarray |
US20050182011A1 (en) | 2003-11-13 | 2005-08-18 | Eric Olson | Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure |
JP4575923B2 (ja) | 2003-12-15 | 2010-11-04 | カレッジ オブ メディスン ポーチョン シーエイチエー ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーション | ヒトES細胞より分離された新規miRNA |
US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
EP1713938A2 (fr) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers |
WO2005079397A2 (fr) | 2004-02-13 | 2005-09-01 | Rockefeller University | Molecules d'oligonucleotides anti-microarn |
US8088902B2 (en) | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
US20060134639A1 (en) | 2004-04-06 | 2006-06-22 | Huffel Christophe V | Method for the determination of cellular transcriptional regulation |
US20050260648A1 (en) | 2004-04-06 | 2005-11-24 | Huffel Christophe V | Method for the determination of cellular transcriptional |
WO2005098029A2 (fr) | 2004-04-07 | 2005-10-20 | Exiqon A/S | Nouvelles methodes permettant de quantifier des micro arn et petits arn interferants |
EP2290074B1 (fr) | 2004-05-28 | 2014-12-17 | Asuragen, Inc. | Procédés et compositions impliquant du microARN |
AU2005272816B2 (en) | 2004-08-10 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
EP2338994B1 (fr) | 2004-09-02 | 2014-03-19 | Yale University | Régulation d'oncogènes par des micro-ARN |
FR2877350B1 (fr) | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
EP2287303B1 (fr) | 2004-11-12 | 2014-07-02 | Asuragen, Inc. | Procédés et compositions impliquant l'ARNmi et des molécules inhibitrices de l'ARNmi |
WO2006063356A1 (fr) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation du controle epigenetique de l'expression genique |
US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
WO2006071884A2 (fr) | 2004-12-27 | 2006-07-06 | The Regents Of The University Of Michigan | Agents therapeutiques a base d'oligonucleotides |
EP1959012A3 (fr) | 2004-12-29 | 2009-12-30 | Exiqon A/S | Nouvelles compositions oligonucléotides et séquences de sonde utiles pour la détection et l'analyse de micro ARN et leurs ARN cibles |
US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
US20070065840A1 (en) | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
JP2006292367A (ja) | 2005-04-05 | 2006-10-26 | Mitsubishi Rayon Co Ltd | miRNA検出用マイクロアレイ |
WO2006108581A2 (fr) | 2005-04-15 | 2006-10-19 | Cenix Bioscience Gmbh | Genes marqueurs humains et agents associes pour le diagnostic, le traitement et la prophylaxie de troubles cardio-vasculaires et d'atherosclerose |
CN101203611B (zh) | 2005-04-19 | 2013-08-14 | 巴斯福植物科学有限公司 | 控制基因表达的改良方法 |
KR20130114758A (ko) | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Mi-rna를 포함하는 유전자 벡터 |
CA2610265A1 (fr) | 2005-05-31 | 2007-05-10 | Cold Spring Harbor Laboratory | Methode de production de micro-arns |
US20070054287A1 (en) | 2005-05-31 | 2007-03-08 | Applera Corporation | Method for identifying medically important cell populations using micro rna as tissue specific biomarkers |
EP1904111A4 (fr) | 2005-06-03 | 2009-08-19 | Univ Johns Hopkins | Compositions et procédés pour diminuer l'expression de microarn pour le traitement de la néoplasie |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
EP1919512B1 (fr) | 2005-08-10 | 2014-11-12 | Alnylam Pharmaceuticals Inc. | Oligonucléotides chimiquement modifiés pouvant être employés dans la modulation de micro-arn et applications |
CN101426912A (zh) | 2005-08-17 | 2009-05-06 | 瑟纳治疗公司 | 介导rna干扰的化学修饰短干扰核酸分子 |
AU2006291165B2 (en) | 2005-09-12 | 2013-03-14 | The Ohio State University Research Foundation | Compositions and methods for the diagnosis and therapy of BCL2-associated cancers |
US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
AU2006315099C1 (en) | 2005-11-21 | 2013-01-10 | Johnson & Johnson Research Pty Limited | Multitargeting interfering RNAs and methods of their use and design |
WO2007087451A2 (fr) | 2006-01-25 | 2007-08-02 | University Of Massachusetts | Compositions et procedes d’accroissement des interferences arn discriminatoires |
EP1986609A2 (fr) | 2006-01-26 | 2008-11-05 | University of Massachusetts | Agents de rna silencing a usage therapeutique et nanotransporteurs pour les delivrer efficacement |
WO2007092181A2 (fr) | 2006-01-26 | 2007-08-16 | Unversity Of Massachusetts | Compositions et méthodes permettant de moduler la répression traductionnelle |
EP2388328A1 (fr) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Composés oligomères et compositions pour une utilisation dans la modulation de micro ARN |
EP1986697B1 (fr) | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions et procédés permettant l'inhibition de silençage de gènes par l'interférence arn |
ES2448491T3 (es) | 2006-03-02 | 2014-03-14 | The Ohio State University Research Foundation | Perfil de expresión de microARN asociado con cáncer de páncreas |
ES2715625T3 (es) | 2006-04-03 | 2019-06-05 | Roche Innovation Ct Copenhagen As | Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN |
US20080220423A1 (en) | 2006-05-19 | 2008-09-11 | Soren Moller | Oligonucleotide probes useful for detection and analysis of microRNA precursors |
WO2007147067A2 (fr) | 2006-06-14 | 2007-12-21 | Rosetta Inpharmatics Llc | Procédés et compositions de régulation de l'évolution du cycle cellulaire |
WO2007147409A2 (fr) | 2006-06-19 | 2007-12-27 | Københavns Universitet | Stabilisation de polynucléotides médiée par des ribozymes |
WO2008024499A2 (fr) | 2006-08-25 | 2008-02-28 | Duke University | PROCÉDÉS D'IDENTIFICATION IN VIVO DE CIBLES D'ARNm ENDOGÈNE DE MICRO ARN |
CA2663962A1 (fr) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Genes regules mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention therapeutique |
WO2008042231A2 (fr) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque |
EP2476762B1 (fr) | 2006-10-09 | 2014-01-08 | Julius-Maximilians-Universität Würzburg | Micro-ARN (miARN) pour le diagnostic et le traitement de maladies cardiaques |
WO2008147430A2 (fr) | 2006-10-11 | 2008-12-04 | Nucleonics, Inc. | Constructions vectorielles d'arn interférant multicible formaté par micro-arn et leurs procédés d'utilisation |
JP2010509923A (ja) | 2006-11-23 | 2010-04-02 | ミルクス セラピューティクス アンパーツゼルスカブ | 標的rnaの活性を変化させるためのオリゴヌクレオチド |
CA2671299A1 (fr) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Fonctions et cibles de microarn let-7 |
WO2008073923A2 (fr) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Gènes et voies régulés par miarn comme cibles d'intervention thérapeutique |
WO2008073921A2 (fr) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Gènes et voies régulés par mir-126 comme cibles d'intervention thérapeutique |
AU2007333107A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
WO2008074328A2 (fr) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Oligos de blocage de sites cibles de microarn et leurs utilisations |
EP3536788A1 (fr) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Oligos de blocage de sites cibles de microarn et leurs utilisations |
US20090175827A1 (en) | 2006-12-29 | 2009-07-09 | Byrom Mike W | miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
WO2008109373A1 (fr) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Composés d'acide nucléique permettant d'inhiber l'expression de gène erbb et utilisations de ceux-ci |
WO2008112226A2 (fr) | 2007-03-13 | 2008-09-18 | Massachusetts Institute Of Technology | Constructions permettant l'immobilisation d'un gène basée sur la technique cre-lox, et leurs procédés d'utilisation |
EP2136846A4 (fr) | 2007-03-26 | 2011-04-13 | Crc For Asthma And Airways Ltd | Cibles therapeutique et molecules |
US9353368B2 (en) | 2007-05-23 | 2016-05-31 | Ge Healthcare Dharmacon, Inc. | Micro-RNA scaffolds and non-naturally occurring micro-RNAs |
KR20100049079A (ko) | 2007-07-18 | 2010-05-11 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 인간의 정상 심장과 기능부진 심장에서 마이크로 rna의 차등 발현 |
WO2009012263A2 (fr) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn |
US20090092980A1 (en) | 2007-07-20 | 2009-04-09 | Christoph Arenz | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES |
WO2009044895A1 (fr) | 2007-10-03 | 2009-04-09 | Kyowa Hakko Kirin Co., Ltd. | Composition inhibant l'expression d'un gène cible |
KR101889518B1 (ko) | 2007-10-04 | 2018-08-17 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 마이크로MIRs |
WO2009058913A2 (fr) | 2007-10-29 | 2009-05-07 | University Of Massachusetts | Nanoparticules encapsulées pour l'administration d'acides nucléiques |
WO2009058818A2 (fr) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprenant un micro-arn et procédés pour leur utilisation dans la régulation du remodelage cardiaque |
AU2008323652B2 (en) | 2007-11-09 | 2014-02-20 | Board Of Regents, The University Of Texas System | Micro-RNAs of the miR-15 family modulate cardiomyocyte survival and cardiac repair |
CA2717792A1 (fr) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Compositions pharmaceutiques pour le traitement de maladies associees aux microarn |
EP2279267A4 (fr) | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | Procédé d'identification de nouveaux candidats thérapeutiques via l'analyse d'expression génique dans les maladies d'origine vasculaire |
EP2105145A1 (fr) | 2008-03-27 | 2009-09-30 | ETH Zürich | Procédé pour la libération spécifique dans les muscles d'oligonucléotides conjugués avec des lipides |
US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
US20100113284A1 (en) | 2008-04-04 | 2010-05-06 | Alexander Aristarkhov | Small interfering rna (sirna) target site blocking oligos and uses thereof |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
WO2009149182A1 (fr) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation de l'expression génique par ciblage d'un petit arn endogène de promoteurs de gènes |
WO2010036939A2 (fr) | 2008-09-26 | 2010-04-01 | University Of Southern California | Système d'expression synergiste de petits éléments d'arn fonctionnels multiples |
EP2358398A2 (fr) | 2008-10-24 | 2011-08-24 | Isis Pharmaceuticals, Inc. | Composés oligomères et méthodes |
WO2010126355A1 (fr) | 2009-04-29 | 2010-11-04 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Moyens et procédés pour contrecarrer, prévenir et/ou déterminer une insuffisance cardiaque ou un risque d'insuffisance cardiaque |
EA022757B1 (ru) | 2009-06-08 | 2016-02-29 | Мираджен Терапьютикс | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК |
-
2013
- 2013-06-19 US US13/921,537 patent/US9163235B2/en not_active Expired - Fee Related
- 2013-06-21 BR BR112014032239A patent/BR112014032239A2/pt not_active IP Right Cessation
- 2013-06-21 CA CA2876105A patent/CA2876105A1/fr not_active Abandoned
- 2013-06-21 CN CN201380039961.7A patent/CN104540527A/zh active Pending
- 2013-06-21 KR KR1020157001535A patent/KR20150036140A/ko not_active Application Discontinuation
- 2013-06-21 IN IN10899DEN2014 patent/IN2014DN10899A/en unknown
- 2013-06-21 MX MX2014015641A patent/MX2014015641A/es unknown
- 2013-06-21 WO PCT/US2013/046960 patent/WO2013192486A1/fr active Application Filing
- 2013-06-21 SG SG11201408460UA patent/SG11201408460UA/en unknown
- 2013-06-21 TW TW102122289A patent/TW201406774A/zh unknown
- 2013-06-21 MD MDA20150006A patent/MD20150006A2/ro not_active Application Discontinuation
- 2013-06-21 JP JP2015518597A patent/JP2015525081A/ja active Pending
- 2013-06-21 EP EP13806131.2A patent/EP2863956A4/fr not_active Withdrawn
- 2013-06-21 EA EA201590070A patent/EA201590070A1/ru unknown
- 2013-06-21 AU AU2013277033A patent/AU2013277033A1/en not_active Abandoned
- 2013-06-24 AR ARP130102219 patent/AR091539A1/es unknown
-
2015
- 2015-10-22 HK HK15110356.0A patent/HK1209621A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2863956A4 (fr) | 2016-01-20 |
WO2013192486A1 (fr) | 2013-12-27 |
BR112014032239A2 (pt) | 2017-08-01 |
EP2863956A1 (fr) | 2015-04-29 |
HK1209621A1 (en) | 2016-04-08 |
KR20150036140A (ko) | 2015-04-07 |
JP2015525081A (ja) | 2015-09-03 |
MD20150006A2 (ro) | 2015-06-30 |
EA201590070A1 (ru) | 2015-04-30 |
AR091539A1 (es) | 2015-02-11 |
MX2014015641A (es) | 2015-07-14 |
CA2876105A1 (fr) | 2013-12-27 |
US9163235B2 (en) | 2015-10-20 |
US20130345288A1 (en) | 2013-12-26 |
TW201406774A (zh) | 2014-02-16 |
CN104540527A (zh) | 2015-04-22 |
AU2013277033A1 (en) | 2015-01-22 |
IN2014DN10899A (fr) | 2015-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408460UA (en) | Inhibitors of the mir-15 family of micro-rnas | |
SG11201909432SA (en) | Compounds for increasing genome editing efficiency | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201901841TA (en) | Targeting ligands | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201900910TA (en) | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201807573VA (en) | Methods for providing single-stranded rna | |
SG11201805927YA (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
SG11201407649RA (en) | Method for treating non-small cell lung cancer | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
SG11201406923WA (en) | Microorganisms and processes for the production of isoprene | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201810294QA (en) | Treatment for parkinson's disease | |
SG11201805184TA (en) | Combination therapy | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201908487YA (en) | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast | |
SG11201806623VA (en) | Bacteria over-expressing c-di-amp and therapeutic methods | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201806783WA (en) | Methods for treatment and prophylaxis of hiv and aids |